Screening platform for healthy aging naturals using human dermal fibroblasts
A screening platform leveraging human dermal fibroblasts to identify natural senolytics and senomorphics for healthy aging. It enables medium throughput screening of compounds and extracts for senescent cell inhibition, with validation processes for enhanced efficacy.
Overview
The screening platform developed by AnalytiCon Discovery GmbH utilizes human dermal fibroblasts (HDF) to identify natural compounds that promote healthy aging. This platform is designed for medium throughput screening to find senolytic and senomorphic agents. By focusing on HDF cells, which are prevalent throughout the human body, the platform aims to discover compounds that can selectively inhibit senescent cells, offering potential benefits in aging-related health, particularly for gut health.
Technical specifications
Key features:
- Utilizes a proprietary collection of thousands of natural compounds, fractions, and plant extracts.
- Performs cytotoxicity screening to determine appropriate dosing of natural samples.
- Generates senescent cells through repeated cell cycles for targeted screening.
- Validates initial hits using SA-beta-Gal assays for senolytics and IL-6+MMP-1 secretion inhibition assays for senomorphics.
- Designed for expansion into in vivo experiments and considerations for regulatory and labeling strategies.
Technology readiness level
The technology is currently at TRL 4, indicating that the platform has been validated in a laboratory setting. Future steps include expansion into in vitro screening, in vivo validation, and scale-up processes, along with regulatory strategy development.
About AnalytiCon Discovery GmbH
AnalytiCon Discovery is a research and development company specializing in natural product chemistry and small molecule compounds. Based in Potsdam, Germany, the company provides end-to-end services for the pharmaceutical, cosmetic, food, and agricultural sectors. Their capabilities span the entire discovery value chain, including the establishment of proprietary substance libraries, identification of active ingredients, synthetic optimization, and commercial-scale production. The company leverages an integrated approach that combines microbiology, natural product isolation, state-of-the-art analytical technologies like NMR and LC/MS, and advanced screening platforms. Since 2013, AnalytiCon has operated as a member of the BRAIN Biotech Group, utilizing specialized laboratories and a team of experts to transform natural molecules into viable, innovative products.
By offering deep expertise in natural product-based discovery, AnalytiCon serves as a critical partner for organizations seeking to overcome the complexities of medicinal chemistry and substance development. They solve significant industry challenges by providing high-quality, fully elucidated compound collections that expedite preclinical discovery projects and research into novel therapeutic targets. Their track record includes numerous successful collaborations with global pharmaceutical and consumer goods companies, focusing on applications such as drug discovery, sugar and calorie reduction, and natural preservation ingredients. Through their combination of technical competence and solution-oriented project management, they enable partners to accelerate the development of sustainable, bio-based products for diverse global markets.
delivered to your inbox.